An immunosuppressive agent, cyclosporin A (CYA), is used for several types of organ transplantation and for many diseases in which an immune reaction is involved. 1) However, this drug may induce adverse effects such as nephrotoxicity at higher concentrations. Therefore, to use it safely and effectively, routine monitoring of the CYA blood concentration is often recommended for the appropriate adjustment of dose, dosage interval, or both.
2) CYA blood concentration exhibits a large intra-and inter-individual variability. In some patients, in spite of the frequent and sophisticated adjustment of the CYA dosage regimen, a sharp fluctuation of CYA blood concentrations was observed in clinical settings, which might cause the adverse effect by the unexpected elevation of the concentration. Therapeutic monitoring of CYA trough blood concentration is accompanied by phlebotomies and drug assays, thus the decrease in the amount of monitoring would contribute to the reduction of the burden for the patients.
In this study, the methodology to distinguish the patients showing considerable fluctuation of CYA trough blood concentrations was subjected to an investigation especially from a viewpoint of laboratory test values. The retrospective examination of the CYA trough blood concentrations monitored routinely suggested that considerable fluctuation of CYA trough blood concentrations was related to the higher concentration of triglyceride in serum but not to the glutamic oxaloacetic transaminase (GOT) activity and the concentrations of creatinine, albumin and total cholesterol in serum, and the hematocrit value. Next, to elucidate the effect of serum triglyceride concentration on the CYA blood concentration, in vivo pharmacokinetic studies, after single intravenous or repetitive oral administration of CYA, were conducted in rats with pseudo-hypertriglyceridemia, hypocythemia, and acute renal failure.
MATERIALS AND METHODS
Reagents Cyclosporin A (CYA) injection was purchased from Novartis Pharma (Basel, Switzerland). Intralipid injection was purchased from Pharmacia AB (Stockholm, Sweden). Cisplatin for injection was purchased from BristolMyers Squibb (Tokyo, Japan). All other chemicals were of the highest purity available.
CYA Trough Blood Concentrations in Patients
The routine monitoring data on the whole blood concentration of CYA were retrospectively analyzed, which were obtained at Kobe University Hospital from November 1998 to September 1999. The data were extracted for the following analysis with inclusion criteria of: 1) CYA trough blood concentration was understood to be at steady-state, 2) more than three points were obtained during the examination period, 3) the difference of CYA daily dose between the maximal (D max ) and minimal (D min ) were less than 100 mg and 4) the laboratory test values during the examination period were clarified. The total number of patients was 78. The fluctuation of CYA trough blood concentrations was evaluated by the ratio of the maximal value of its trough concentrations to the minimal one during the examination period (C max /C min ). The patients were classified into three groups: Group 1 (C max /C min ϭ100-200%; n=21), Group 2 (C max /C min =200-300%; n=25), and The methodology to distinguish the patients showing considerable fluctuation of the whole blood concentration of cyclosporin A (CYA) was investigated from a viewpoint of laboratory test values. First, we retrospectively examined the CYA trough blood concentrations monitored continuously. The patients were classified into three groups by the fluctuation of CYA trough blood concentrations during the examination period (C max /C min ): Group 1 (C max /C min ‫;%002-001؍‬ n‫,)12؍‬ Group 2 (C max /C min ‫;%003-002؍‬ n‫,)52؍‬ and Group 3 (C max /C min ‫؍‬more than 300%; n‫.)23؍‬ In the laboratory tests examined, the serum triglyceride concentrations were considerably different among the groups, and it was the highest in Group 3. Next, to elucidate the effect of serum triglyceride concentration on the CYA blood concentration, in vivo pharmacokinetic studies after single intravenous or repetitive oral administration of CYA were conducted in the model rats with pseudo-hypertriglyceridemia, hypocythemia, and acute renal failure. Only in pseudo-hypertriglyceridemia rats, the CYA blood concentration after a single intravenous injection was significantly higher than that in normal rats because of the restriction of CYA distribution to the extravascular tissues. Group 3 (C max /C min ϭmore than 300%; n=32).
Model Rats with Pseudo-hypertriglyceridemia, Hypocythemia and Acute Renal Failure for in vivo Pharmacokinetic Study The animal experiments were performed in accordance with the Guideline for Animal Experiments of Kobe University. Male Slc: Wistar albino rats (200-250 g) were used. In vivo pharmacokinetic studies after a single intravenous or repetitive oral administration of CYA were conducted in rats with pseudo-hypertriglyceridemia, hypocythemia or acute renal failure. Pseudo-hypertriglyceridemia was induced by intravenous injection of lipid emulsion (Intralipid Injection, Pharmacia AB, soybean oil 20 g/dl, egg yolk phosphatides 2.4 g/dl, 2.0 g/kg body weight) at 30 min before CYA administration. Hypocythemia was induced by intravenous injection of about 2.5 ml plasma at 1 d before CYA administration, which was prepared by centrifuging 5.0 ml of the blood obtained from the same animals. Acute renal failure was induced by an intraperitoneal administration of cisplatin (10 mg/20 ml/kg body weight) at 3 d before CYA administration.
Single Intravenous Injection of CYA to Rats Normal and model rats were used after overnight fasting and under a light ether anesthesia. The right jugular vein of each rat was cannulated for blood sampling at least 2 d prior to experiments and the free end of this cannula with physiological saline was directed subcutaneously to the dorsal side of the neck. CYA was administered intravenously at a dose of 10 mg/ml/kg in each group. Blood samples were drawn from the right jugular vein into EDTA-containing polyethylene tubes (final concentration 0.1%) prior to and at 2, 5, 15, 30, 60 and 120 min after CYA injection for the determination of CYA blood concentration according to the procedure presented below. Additional blood samples were obtained prior to and at 120 min after CYA injection and immediately centrifuged at room temperature to determine the hematocrit value. Blood samples were also obtained prior to and at 120 min after CYA injection into EDTA free tubes to prepare serum and determine the GOT activity and the concentration of creatinine, albumin and triglyceride in serum.
Tissue Distribution of CYA after Single Intravenous Injection to Rats Normal rats and rats with pseudo-hypertriglyceridemia were used after overnight fasting and under a light ether anesthesia. CYA was administered intravenously at a dose of 10 or 20 mg/ml/kg. At 5 min after CYA injection, blood samples were drawn from the right jugular vein into EDTA-containing polyethylene tubes (final concentration 0.1%) and rats were killed by the intravenous injection of pentobarbital. The liver, kidneys, heart and muscle tissues were removed and blotted. After weighing, they were homogenized with a 9-fold volume of purified water for the measurement of the CYA tissue concentration. The standard lines for CYA tissue concentration were constructed in advance by using CYA free homogenates. It had been confirmed that CYA were stable during this assay procedures.
Repetitive Oral Administration of CYA to Rats Normal rats and rats with pseudo-hypertriglyceridemia or hypocythemia were used. The lipid emulsion was intravenously injected at 30 min before each blood sampling to maintain pseudo-hypertriglyceridemia. This repetitive injection of lipid emulsion was also conducted on rats with hypocythemia (referred to pseudo-hypertriglyceridemiaϩ hypocythemia). CYA was given by the intravenous loading injection of CYA (0.25 mg/kg) from the femoral vein, and subsequently by repetitive oral administration of CYA solution at doses of 2.5 mg/25 ml/kg at 12 h intervals for 3 d. Blood samples were drawn from the right jugular vein into EDTA-containing polyethylene tubes (final concentration 0.1%) at 36, 48, and 60 h after CYA loading injection for the determination of CYA blood concentration. Additional blood samples were obtained to determine the GOT activity and the concentrations of creatinine, albumin and triglyceride in serum, and the hematocrit value.
Analytical Methods Blood, serum and homogenate samples were stored at Ϫ20°C until analysis. CYA concentrations in blood and homogenate were measured by means of monoclonal fluorescence polarization immunoassay using the TDx operation system (Abbott Laboratory, North Chicago, IL, U.S.A.) according to the manufacturer's manual. The GOT activity and the concentrations of creatinine, albumin and triglyceride in serum were measured by the Reitman-Frankel method, the Jaffé method, the BCG method and the acetyl-acetone method, respectively, by using the diagnosis kits (Wako Pure Chemical Industries, Ltd., Osaka, Japan). Hematocrit values were measured by extensive centrifugation.
Data Analysis The pharmacokinetic parameters in rats were calculated from the individual CYA blood concentration-time curve after intravenous injection by a non-compartment model using the pharmacokinetic software package WinNonlin TM Ver. 2.1 (Pharsight Co., Mountain View, CA, U.S.A.). The pharmacokinetic parameters explored included the area under the blood concentration-time curve (AUC ) and the mean residence time (MRT ). The AUC was calculated by the trapezoidal method from 0 to 120 min. The tissue-to-blood partition coefficient (K p ) was calculated by dividing the tissue concentration by the blood concentration. As for the repetitive oral administration of CYA, variability of CYA trough blood concentration was evaluated by the ratio of its maximal concentration at trough level to the minimal one (C max /C min ).
Statistical Analysis Statistical significance of differences between mean values were calculated using the nonpaired t-test, providing that the variances of groups were similar. If this was not the case, Mann-Whitney's U-test was applied. Multiple comparisons were performed by analysis of variance (ANOVA) followed by Sheffé's test for multiple comparisons, providing that the variances of groups were similar. If this was not the case, a Sheffé-type test following Kruskal-Wallis analysis was applied. p values of less than 0.05 (two-tailed) were considered to be significant.
RESULTS

CYA Trough Blood Concentrations in Patients
When the patients were classified by the fluctuation of CYA trough blood concentrations (C max /C min ), about 70% of them showed C max /C min values of 200% or more. Table 1 lists the characteristics of patients in this study. The age, body weight and daily dose were comparable among three groups. The C max /C min values correlated poorly with the variability of their CYA doses (D max /D min ) (Fig. 1) . The GOT activities and the creatinine concentrations in serum were within their respective normal ranges for all groups (9-36 IU/ml and 0.5-1.3 mg/dl, respectively). The serum albumin concentrations seemed to be below the normal level (4.1-5.0 g/dl), and there might be very slight differences among the groups. Serum cholesterol concentrations for all groups were around the upper limit of normal range (146-219 mg/dl). In contrast, the serum triglyceride concentrations were considerably different among the groups, and it was the highest in Group 3. Most patients in Group 3 showed over the normal range (28-149 mg/dl). The hematocrit values were around the lower limit of normal range (39.0-52.0% for males, 35.0-44.5% for females) for all groups.
Single Intravenous Injection of CYA to Model Rats with Pseudo-hypertriglyceridemia, Hypocythemia, and Acute Renal Failure To elucidate the effect of serum triglyceride concentration on the blood concentration-time profile of CYA, an in vivo pharmacokinetic study was conducted after a single intravenous injection using the model rats. Table 2 shows the time-profiles of serum triglyceride concentration after an intravenous injection of commercially obtained lipid emulsion at the dose of 2.0 g/kg body weight. The serum triglyceride concentration decreased immediately after the injection of the lipid emulsion, and therefore, a continuously higher level of serum triglyceride concentration, that is, hypertriglyceridemia, was not attained. A higher dose or an intraperitoneal injection also failed to attain the higher level. Thus, for the following experiments, the rats with pseudo-hypertriglyceridemia were obtained by intravenous injection of lipid emulsion at 30 min before CYA administration. In this context, the model rats with hypocythemia or acute renal failure were also prepared and the data were compared with the normal rats. Figure 2 shows the CYA blood concentration-time profiles after the single intravenous injection of CYA to the model rats. Table 3 summarized the laboratory test values and pharmacokinetic parameters of CYA. Pretreatment by lipid emulsion injection, back-injection of plasma, and cisplatin resulted in considerable alteration of serum triglyceride concentration, hematocrit value and serum creatinine concentration, respectively. In the presence of pseudo-hypertriglyceridemia, the CYA blood concentration was markedly increased, and AUC was about 2-fold increased and MRT was decreased, compared with those in the normal rats ( Fig. 2 and Table 3 ). In contrast, there was no important alteration of CYA blood concentration-time profiles for rats with hypocythemia or acute renal failure ( Fig. 2 and Table 3 ). Table 4 shows the ratios of CYA concentrations in the liver, kidneys, heart, and muscle tissue to the CYA blood concentrations in the presence or absence of pseudo-hypertriglyceridemia. At 5 min after the 10 mg/kg CYA administration, the tissue-to-blood concentration ratios in rats with pseudohypertriglyceridemia were 2.53Ϯ0.43, 1.59Ϯ0.11, 1.08Ϯ 0.07 and 0.23Ϯ0.01, respectively, being significantly smaller than those in the normal rats: 7.46Ϯ0.39, 4.91Ϯ0.47, 3.42Ϯ0.29 and 0.70Ϯ0.03, respectively. These ratios were also decreased in normal rats when treated with 20 mg/kg of CYA, and this was due to the increase in the CYA blood concentration. However, the alteration was not so predominant when compared with pseudo-hypertriglyceridemia rats. Effect of pseudo-hypertriglyceridemia was decreased or disappeared at 120 min after the CYA administration.
Tissue Distribution of CYA after Single Intravenous Injection to Model Rats with Pseudo-hypertriglyceridemia
Repetitive Oral Administration of CYA to Model Rats with Pseudo-hypertriglyceridemia and Hypocythemia Table 5 shows the effects of pseudo-hypertriglyceridemia and hypocythemia on the maximal and minimal values of CYA blood concentrations, C max and C min , and the fluctuation of CYA blood concentrations (C max /C min ), after its repetitive oral administration. Although the serum triglyceride concentration was significantly increased, no significant effect was observed.
DISCUSSION
CYA exhibits a large intra-and inter-individual variability of its pharmacokinetics, and some patients have a sharp fluctuation of its blood concentrations. In fact, our retrospective study showed that the C max /C min ratios of CYA trough concentrations at a steady state were beyond 200% in about 70% of the patients, in spite of the small variability of their CYA doses, suggesting that the CYA concentration increased unexpectedly, thereby adverse effects might occur (Fig. 1) . Therefore, it is required to distinguish the patients who have a large fluctuation in advance of CYA administration. In the present study, to figure out some indices to distinguish such patients, we first investigated the characteristics of the patients who had a large variability of CYA trough blood concentrations from the viewpoint of laboratory test values The rats were intravenously administered at the dosage of 10 mg/kg. Each point represents the meanϮstandard deviation of more than four rats. * pϽ0.05, significantly different from the normal rats. CYA (10 mg/kg) was administered intravenously in rats with pseudo-hypertriglyceridemia, hypocythemia, and acute renal failure. Each value is the meanϮS.E. of the mean. * pϽ0.05, significantly different from the normal rats. The animals were administered at an oral dose of CYA (2.5 mg/kg) twice a day for (Table 1 ). The results showed that the albumin and hematocrit appeared to be under the respective normal levels and that the serum triglyceride concentration tended to have a positive correlation with the C max /C min ratio of CYA. Some investigators have reported that the day to day change of the concentration of CYA in serum or blood was almost consistent with that of triglyceride in serum. [3] [4] [5] These findings and our retrospective research suggested that the serum triglyceride level was an important factor for the prediction of not only the concentration-time profile of CYA but also the fluctuation of its trough blood concentrations.
Triglycerides, which are components of lipoproteins in blood, and hematocrit are important factors influencing the pharmacokinetics of CYA, because CYA is a highly lipophilic drug and is almost bound to lipoproteins or erythrocytes in blood. [6] [7] [8] It was therefore considered that the fluctuation of CYA trough blood concentrations was deeply related to its distribution into them. In this study, the pharmacokinetics of CYA was next examined in rats with or without pseudo-hypertriglyceridemia, hypocythemia, and acute renal failure. As shown in Fig. 2 , the higher blood concentration of CYA was observed in the pseudo-hypertriglyceridemia group, but not in the hypocythemia and acute renal failure groups. This could be explained by the significant reduction in the tissue distribution of CYA (Table 4 ). In the previous report, with normal rats treated with 10 mg/kg of CYA, the distribution into liver, kidneys, and heart was suggested to attain a steady-state at 5 min.
9) The tissue distribution of CYA was restricted in the pseudo-hypertriglyceridemia rats, as compared with in the normal rats, at about 30 mg/ml of CYA in blood. Therefore, the alteration of CYA blood concentration by pseudo-hypertriglyceridemia would be attributed not to the saturation of its distribution to the tissues but to the predominance of that to the lipoproteins in blood (Table 4 and Fig. 2) . Besides, in pseudo-hypertriglyceridemia rats, it was considered that the oil particles containing CYA, with a diameter of about 200 nm, were entrapped by a reticuloendothelial system with a half-life of about 40 min, which would cause the significant reduction of MRT (11) .
The fluctuation of CYA trough blood concentrations after the repetitive oral administration was further evaluated, concluding that there was no significant effect of pseudo-hypertriglyceridemia (Table 5) . Collectively, the pseudo-hypertriglyceridemia determines the CYA blood concentration itself, but provides no effect on the fluctuation of CYA trough blood concentrations. In other words, the fluctuation of CYA trough blood concentrations observed in the clinical situation could be due to the fluctuation of serum triglyceride concentration.
We investigated the relationship between the fluctuation of CYA trough blood concentrations and laboratory test values, and the effect of serum triglyceride concentration on the CYA blood concentration-time profile was examined using model rats. It was concluded that serum triglyceride concentration was determinant of CYA blood concentration, and the fluctuation of CYA trough blood concentrations observed in the clinical situation could be due to the fluctuation of serum triglyceride concentration. Hopefully, the patients with such fluctuation of serum triglyceride concentration might be distinguishable by the higher concentration of serum triglyceride in laboratory tests. These findings provide useful information to distinguish the patients showing considerable fluctuation of CYA blood concentrations.
